Lopinavir used for preparing medicine for guarding against or treating ischemic cardiovascular and cerebrovascular disease

A cardiovascular and cerebrovascular disease, ischemic technology, applied in the direction of cardiovascular system diseases, drug combination, pharmaceutical formula, etc., can solve the problem of prevention or treatment of ischemic cardiovascular and cerebrovascular diseases, pharmacological effects have not been reported, etc.
CN104095853AInactive Publication Date: 2014-10-15BINZHOU MEDICAL COLLEGE
0 Cites 1 Cited by

Patent Information

Authority / Receiving Office
CN Β· China
Patent Type
Applications(China)
Current Assignee / Owner
BINZHOU MEDICAL COLLEGE
Publication Date
2014-10-15
Estimated Expiration
Not applicable Β· inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the new application of medicine and particularly relates to lopinavir which can be used for guarding against or treating ischemic cardiovascular and cerebrovascular diseases through restraining the expression of HMG (High Mobility Group Protein) B1. According to the invention, the dosage range is 120 mg-6000 mg and 120-3000 mg of lopinavir is particularly preferred.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a new application of medicine, in particular to preventing or treating ischemic cardiovascular and cerebrovascular diseases by inhibiting the expression of HMGB1 with lopinavir. Background technique

[0002] Ischemic stroke is a major disease that seriously endangers human health. Theoretical treatment methods include: (1) Thrombolytic therapy within 3-6 hours after onset. (2) Neuroprotective treatment of secondary nerve damage caused by ischemia. (3) Nerve repair promotes synaptic remodeling and regeneration of surviving nerve cells, including neuroregeneration and neurogenesis. Early thrombolytic therapy is currently recognized as the most effective method, but the treatment time window is narrow, and the indications must be strictly controlled. Currently, only about 3% to 5% of patients can receive thrombolytic therapy. Therefore, neuroprotection has become an important part of the treatment of ischemic stroke, which is d...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More